DailyIQ
Last updated1 minute ago

VTRS·Viatris Inc.

$16.88
-0.06 (-0.35%)
Market Closed (Overnight)$16.96+0.08 (+0.47%)
High
$17.02
Open
$16.81
Market Cap
19.73B
52W High
$18.39
Low
$16.66
P. Close
$16.88
P/E
-
52W Low
$9.42
Fwd P/E
6.33
DailyIQ Est.
$19.20
Inst. Ownership
47.4%
Short Interest
3.18%
Days to Cover
3.0
Technical Score (1D)
73
BUY
News Sentiment
52
MIXED
Viatris’ latest earnings call, released 72 hours ago, highlighted a 4.9 % year‑over‑year revenue rise to $3.76 billion and a non‑GAAP EPS of $0.69, beating consensus by 15 %. The company reiterated its 2026 revenue guidance at $14.75 billion, underscoring confidence in its generics pipeline and cost‑control initiatives. This lift, combined with a $1.15 billion share‑repurchase program completed earlier in the year, signals management’s belief that the stock is undervalued and that cash flow will support further shareholder returns. The announcement is likely to lift short‑term sentiment, as investors weigh the upside potential against lingering pricing and supply headwinds that have kept the stock trading at a 12 % discount. In the same period, analysts noted that Viatris’ China business is more resilient than feared, with retail and e‑commerce sales now accounting for roughly half of the region’s revenue, offsetting hospital volume limits. The stronger margins and rising profit contribution in China should cushion the company from the new volume‑control policy, providing a modest upside to the overall outlook. However, the company’s ongoing supply‑chain disruptions and the need to maintain launch cadence remain key risks that could temper near‑term growth. Looking ahead, traders should monitor the pace of new product launches and the execution of cost‑control measures, as these will determine whether the company can sustain its margin improvement and meet the raised guidance. Additionally, the timing of the remaining $70 million contingent payment for the Tyrvaya sale in 2026 could affect earnings in the second half of the year. Finally, any further updates on China’s regulatory environment or on the company’s pipeline approvals will be critical to gauge whether the valuation gap narrows further.
Earnings Summary
Viatris Inc. is a global healthcare company that develops, manufactures, and distributes prescription brand drugs, generics, complex generics, and biosimilars across North America, Europe, China, and emerging markets. In the last two quarters, revenue increased from $3.517 billion in Q1 2026 to $3.757 billion in Q2 2026, a 7.1% YoY rise, while EPS grew from $0.59 to $0.69, maintaining a positive earnings trend; the company has consistently beat earnings estimates in all reported quarters, with a 21% jump in Greater China sales driving a recent revenue guidance lift to $14.75 billion for 2026. Historically, Viatris has shown steady YoY revenue growth and EPS improvement, with consistent beats against analyst estimates, reflecting a resilient generic drug portfolio and effective cost controls. Recent news highlights new product launches expected to lift operating leverage, a divestiture of the Tyrvaya line freeing capital for core portfolio expansion, and a 21% increase in Greater China sales prompting a revenue guidance upgrade; the company’s focus on restoring supply chains and tightening cost controls is expected to offset price erosion on older high‑value generics. Investors should watch for the speed and scale of new product launch execution, any signs of cost overruns or supply‑chain bottlenecks, and regulatory updates that could affect pricing or approval timelines, as these factors will determine whether the raised guidance holds.

EPS

EstBeatMiss
$0.53$0.58$0.62$0.67$0.71Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.65 - -
Q2'26$0.61$0.69+12.6%
Q1'26$0.61$0.59-3.4%
Q4'25$0.55$0.57+3.4%
Q3'25$0.62$0.67+8.5%
Q2'25$0.56$0.62+11.6%

Revenue

EstBeatMiss
$3.3B$3.4B$3.6B$3.8B$4.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.9B - -
Q2'26$3.8B$3.8B+0.1%
Q1'26$3.4B$3.5B+2.7%
Q4'25$3.3B$3.7B+10.7%
Q3'25 - $3.8B -
Q2'25 - $3.6B -

Market Data

VTRS Stock Snapshot

BUY73/100
$16.96+$0.08 (0.5%)
Market cap
19.73B
Day range
$16.66 – $17.02
News sentiment
52/100 · Neutral
Analyst target
$18.50 (+9.1%)
Consensus
Buy · 18 analysts
52-week range+80.0% off low · -7.8% from high
$9.42$18.39
Price $16.96 DailyIQ Est. $19.20

The signal on VTRS is bullish: price action is confirming the underlying trend, not fighting it. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into VTRS?

CHEAP

At today's price, Viatris Inc. needs to grow free cash flow about -8.2% a year for the next 10 years to justify its valuation at a 6.26% cost of capital. Over its actual history it has compounded free cash flow at 3.9% a year, so the market is asking for 12.1 percentage points below its own delivered rate. On that basis VTRS looks priced below what its own growth record supports.

Implied FCF growth
-8.2%
Historical FCF CAGR
3.9%
Growth gap
-12.1 pts
Verdict
CHEAP
Discount rate (WACC)
6.26%
Beta
0.80

Behaviour On Record

What VTRS's own history says about today's numbers

Realized volatility (21d)
36.6% 70th pct
Below its peak
-77.6%
vs 200-day average
+15.7%
Up days (1y)
54%

Viatris Inc. is currently running 36.6% annualised volatility over the last 21 sessions. Measured against VTRS's own 13 years of daily returns rather than a market-wide average, that is the 70th percentile a little above its own norm, against a typical reading of 30.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

VTRS is trading -77.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -39.1%, and the deepest was -48.1% in 2015. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +15.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 90th percentile a wider gap than this stock usually carries. Over the past year VTRS closed higher on 54% of sessions, and it is currently 1 session into a falling streak.

On September specifically: over 13 years of records, VTRS finished the month higher 2 of 13 times, with a median return of -6.4% and an average of -5.2%. Its strongest month historically has been November at +4.9% on average, its weakest March at -5.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: VTRS has opened more than 2% away from the prior close in 148 of 3,268 sessions (4.5% of the time), with the largest gaps running +9.8% and -5.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, VTRS moved an average of 1.5% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.5% and a largest of -2.0%.

All figures computed from 3,269 daily closes between 2013-09-05 and 2026-09-03, split-adjusted, recomputed daily. Percentiles are against VTRS's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of VTRS's sector?

Viatris Inc. sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#2 of 11
Sector state
Weakening
Sector rotation score
90

Options Market

What is the options market pricing for VTRS?

CallsPuts

For Viatris Inc.'s nearest expiry (2026-09-18, 13 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.43), with at-the-money implied volatility around 86.1%. The options market is pricing roughly a ±12.5% move by that expiry — a range of about $14.27–$18.33.

Put/call ratio (2026-09-18)
0.43
ATM implied volatility
86.1%
Total open interest
6,527
Expected move by 2026-09-18
±12.5% ($14.27–$18.33)

VTRS Competitive Positioning

Viatris Inc. (VTRS) is tracked alongside these names in Drug Manufacturers - Specialty & Generic on DailyIQ — ranked by market cap, with today's move alongside.